<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Background and objectives</bold>: Polycystic ovary syndrome (PCOS) displays a phenotype-dependent cardio-metabolic risk. By performing a systematic search of the literature, we aimed to summarize metabolomic signatures associated with obesity in PCOS women.<bold>Data sources and study eligibility criteria</bold>: We conducted a comprehensive search including: Embase, PubMed, and Web of Science until 31st of May 2019. We used the terms: metabolomics and polycystic ovary syndrome. We excluded the following papers: animal studies, studies that included only lean PCOS women, reviews, meta-analyses, results of interventional studies, those that did not apply metabolomic techniques.<bold>Results</bold>: The lipid signature in obese women with PCOS showed increased levels of free fatty acids (carnitine, adipic acid, linoleic acid, oleic acid) and lower levels of lysophosphatidylcholines and glycerolphosphocholine compared with non-obese PCOS women. Regarding carbohydrate metabolism, a decrease in citric and lactic acid levels characterized obese PCOS women. Decreased lactic acid in obese PCOS women suggests augmented insulin stimulated glucose muscle use in lean, but not in obese women. Considering amino acid metabolomic markers, valine, glycine, serine, threonine, isoleucine and lysine were higher in obese PCOS women. Patients with visceral obesity presented a diminished uptake of essential amino acids, BCAA, leucine and serine in the skeletal muscle. α-ketoglutarate was significantly higher in obese women with PCOS in comparison with lean women with PCOS, distinguishing these 2 subgroups of PCOS with high ‘predictive accuracy’.<bold>Limitations</bold>: Overall, a small number of studies have focused on the impact of obesity on the metabolic fingerprints of PCOS women. There is need for properly controlled, high-quality studies.<bold>Conclusions</bold>: There is compelling evidence of significant alterations in carbohydrate, lipid, and amino acid metabolism in women with PCOS and obesity. Metabolomics may identify new metabolic pathways involved in PCOS and improve our understanding of the complex relation between PCOS and obesity in order to personalize PCOS therapy.</abstract>

Background and objectives: Polycystic ovary syndrome (PCOS) displays a phenotype-dependent cardio-metabolic risk. By performing a systematic search of the literature, we aimed to summarize metabolomic signatures associated with obesity in PCOS women.Data sources and study eligibility criteria: We conducted a comprehensive search including: Embase, PubMed, and Web of Science until 31st of May 2019. We used the terms: metabolomics and polycystic ovary syndrome. We excluded the following papers: animal studies, studies that included only lean PCOS women, reviews, meta-analyses, results of interventional studies, those that did not apply metabolomic techniques.Results: The lipid signature in obese women with PCOS showed increased levels of free fatty acids (carnitine, adipic acid, linoleic acid, oleic acid) and lower levels of lysophosphatidylcholines and glycerolphosphocholine compared with non-obese PCOS women. Regarding carbohydrate metabolism, a decrease in citric and lactic acid levels characterized obese PCOS women. Decreased lactic acid in obese PCOS women suggests augmented insulin stimulated glucose muscle use in lean, but not in obese women. Considering amino acid metabolomic markers, valine, glycine, serine, threonine, isoleucine and lysine were higher in obese PCOS women. Patients with visceral obesity presented a diminished uptake of essential amino acids, BCAA, leucine and serine in the skeletal muscle. α-ketoglutarate was significantly higher in obese women with PCOS in comparison with lean women with PCOS, distinguishing these 2 subgroups of PCOS with high ‘predictive accuracy’.Limitations: Overall, a small number of studies have focused on the impact of obesity on the metabolic fingerprints of PCOS women. There is need for properly controlled, high-quality studies.Conclusions: There is compelling evidence of significant alterations in carbohydrate, lipid, and amino acid metabolism in women with PCOS and obesity. Metabolomics may identify new metabolic pathways involved in PCOS and improve our understanding of the complex relation between PCOS and obesity in order to personalize PCOS therapy.

Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature

”Iuliu Hatieganu” University of Medicine and Pharmacy

6th Department of Medical specialities, Diabetes and Nutrition Diseases

6th Department of Medical specialities Endocrinology

“Iuliu Hatieganu” University of Medicine and Pharmacy

Department of Cardiology and Internal Medicine I

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of TarguMures

Revista Romana de Medicina de Laborator

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Background and objectives: Polycystic ovary syndrome (PCOS) displays a phenotype-dependent cardio-metabolic risk. By performing a systematic search of the...

Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature

Published Online: Jul 27, 2020

Page range: 241 - 255

Received: Dec 09, 2019

Accepted: Feb 13, 2020

DOI: https://doi.org/10.2478/rrlm-2020-0017

Keywords
untargeted metabolomics, polycystic ovary syndrome, obesity, biomarkers, targeted metabolomics

© 2020 Camelia Larisa Vonica et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature

Published Online: Jul 27, 2020

Page range: 241 - 255

Received: Dec 09, 2019

Accepted: Feb 13, 2020

DOI: https://doi.org/10.2478/rrlm-2020-0017

Keywordsuntargeted metabolomics, polycystic ovary syndrome, obesity, biomarkers, targeted metabolomics

© 2020 Camelia Larisa Vonica et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Keywords
untargeted metabolomics, polycystic ovary syndrome, obesity, biomarkers, targeted metabolomics